News and Announcements
Analyticas’ AutoStart Burette Listed Through Queensland Health Tender
- Published June 06, 2016 2:41PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
3rd June 2016, ASX Announcement
Analytica (ASX: ALT) is pleased to announce that the AutoStart® infusion system product has been listed on the Queensland Health purchasing schedule. The product was listed by Medical Australia Ltd (ASX: MLA) the Australian sponsor of the device under their Tuta FirstFlow® brand name.
Inclusion in the schedule is a pre-requisite for all public Queensland health facilities to purchase medical devices and other health products. The listing will be reviewed in 2019.
Chairman Dr Michael Monsour said “The listing is another milestone achieved in the commercialisation of the AutoStart infusion system. It allows the product to be purchased by any Queensland Health hospital or health clinic and we aim to list in other states as tenders fall due.”
To view the full announcement, please click on the button below.
Company Updates
The Yield Illusion: Inside RAM’s Strategy to Withstand the Credit Shakeout
As interest rates reprice in 2026, the rush into private credit has created a dangerous trap for yield-hungry investors. Real Asset Management Group CEO Scott Kelly exposes the “yield illusion” dominating the market and explains why an origination-led, low-arrears mortgage strategy is the ultimate defense against an impending credit shakeout.
Office sector ‘unloved’ no more: Acure’s $80m Brisbane bet
While institutional investors remain wary of the office sector, Acure Asset Management is doubling down. Founder Angelo Del Borrello explains the “unloved” asset strategy behind his latest $80 million Brisbane acquisition and why the 2032 Olympics are creating a unique arbitrage opportunity for private syndicates.
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
Backed By Leading Investment Groups and Family Offices
